Therapeutic strategies for cytomegalovirus infection in haematopoietic transplant recipients: a focused update.

about

The coming of age of adoptive T-cell therapy for viral infection after stem cell transplantation.Distribution and effects of amino acid changes in drug-resistant α and β herpesviruses DNA polymerase Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation.

P2860

Q35477534-96E537F8-4A2F-44D6-A0CE-6AD4C7D2A2FD Q37523020-BF52E604-74B7-4625-834F-0C276FCCBD7D Q38797660-EE28F8C4-66E5-4997-9031-7D456021AC13

P2860

Therapeutic strategies for cytomegalovirus infection in haematopoietic transplant recipients: a focused update.

Item

http://www.wikidata.org/entity/Q38206823

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Therapeutic strategies for cyt ...... recipients: a focused update.

@en

type

Item

label

Therapeutic strategies for cyt ...... recipients: a focused update.

@en

prefLabel

Therapeutic strategies for cyt ...... recipients: a focused update.

@en

P1476

Therapeutic strategies for cyt ...... recipients: a focused update.

@en

P2093

Karl S Peggs

http://www.w3.org/2001/XMLSchema#string

Rob S Sellar

http://www.w3.org/2001/XMLSchema#string

P2860

Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial.

Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH/gL/pUL128-130-131 complex during primary infection

Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient.

Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation

Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients.

Maribavir and human cytomegalovirus-what happened in the clinical trials and why might the drug have failed?

Therapeutic strategies for the prevention and treatment of cytomegalovirus infection.

Maribavir use in practice for cytomegalovirus infection in French transplantation centers.

Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial.

CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation.

P304

1121-1126

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712598.2014.908847

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-04-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24762099

http://www.w3.org/2001/XMLSchema#string

P921

Cytomegalovirus

Therapeutic strategies for cytomegalovirus infection in haematopoietic transplant recipients: a focused update.

about

P2860

P2860

Therapeutic strategies for cytomegalovirus infection in haematopoietic transplant recipients: a focused update.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921